Compounds > 5-hydroxy-6-methoxy-2-indolylcarboxylic acid

Page last updated: 2024-12-08

5-hydroxy-6-methoxy-2-indolylcarboxylic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

5-hydroxy-6-methoxy-2-indolylcarboxylic acid: metabolite found in urine of mammals having melanotic melanoma [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID Source	ID
PubMed CID	160640
SCHEMBL ID	6285596
MeSH ID	M0068116

Synonyms (15)

Synonym
2495-80-9
5-hydroxy-6-methoxy-1h-indole-2-carboxylic acid
hmica
6-methoxy-5-oxidanyl-1h-indole-2-carboxylic acid
A819868
5-hydroxy-6-methoxy-2-indolecarboxylic acid
5-hydroxy-6-methoxy-2-indolylcarboxylic acid
5-hydroxy-6-methoxyindole-2-carboxylic acid
5-hydroxy-6-methoxyindole-2-carboxylic
SCHEMBL6285596
DTXSID20179661
D85394
WS-00716
5-hydroxy-6-methoxy-1h-indole-2-carboxylicacid
1h-indole-2-carboxylic acid, 5-hydroxy-6-methoxy-

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (15)

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	7 (46.67)	18.7374
1990's	7 (46.67)	18.2507
2000's	1 (6.67)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.28

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

Metric	This Compound (vs All)
Research Demand Index	11.28 (24.57)
Research Supply Index	2.89 (2.92)
Research Growth Index	4.17 (4.65)
Search Engine Demand Index	0.00 (26.88)
Search Engine Supply Index	0.00 (0.95)

This Compound (11.28)

All Compounds (24.57)

Study Types

Publication Type	This drug (%)	All Drugs (%)
Trials	1 (6.25%)	5.53%
Reviews	1 (6.25%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	14 (87.50%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Trials	Classes	Roles
dihydroxyphenylalanine Dihydroxyphenylalanine: A beta-hydroxylated derivative of phenylalanine. The D-form of dihydroxyphenylalanine has less physiologic activity than the L-form and is commonly used experimentally to determine whether the pharmacological effects of LEVODOPA are stereospecific.. dopa : A hydroxyphenylalanine carrying hydroxy substituents at positions 3 and 4 of the benzene ring.	3.79	2	1	hydroxyphenylalanine; non-proteinogenic alpha-amino acid; tyrosine derivative	human metabolite
5,6-dihydroxyindole [no description available]	1.96	1	0	dihydroxyindole	mouse metabolite
5,6-dihydroxy-2-indolylcarboxylic acid 5,6-dihydroxyindole-2-carboxylic acid : A dihydroxyindole that is indole-2-carboxylic acid substituted by hydroxy groups at positions 5 and 6.	2.37	2	0	dihydroxyindole	mouse metabolite
5-s-cysteinyldopamine [no description available]	2.38	2	0	S-conjugate
6-hydroxy-5-methoxy-2-indolylcarboxylic acid 6-hydroxy-5-methoxy-2-indolylcarboxylic acid: metabolite found in urine of mammals having melanotic melanoma	5.96	8	1
2-s-cysteinyldopa 2-S-cysteinyl-DOPA : An L-tyrosine derivative that is L-DOPA in which the hydrogen at position 2 on the phenyl ring is replaced by a cysteinyl group. Found in the urine of patients with melanoma.	1.97	1	0	amino dicarboxylic acid; aryl sulfide; catechols; diamine; L-tyrosine derivative; S-conjugate; S-organyl-L-cysteine	human urinary metabolite
5-hydroxy-6-methoxyindole 5-hydroxy-6-methoxyindole: from supernatant of melanoma cell culture	2.37	2	0
bilirubin [no description available]	1.96	1	0	biladienes; dicarboxylic acid	antioxidant; human metabolite; mouse metabolite
silicon Silicon: A trace element that constitutes about 27.6% of the earth's crust in the form of SILICON DIOXIDE. It does not occur free in nature. Silicon has the atomic symbol Si, atomic number 14, and atomic weight [28.084; 28.086].	1.96	1	0	carbon group element atom; metalloid atom; nonmetal atom
cysteinyldopa Cysteinyldopa: Found in large amounts in the plasma and urine of patients with malignant melanoma. It is therefore used in the diagnosis of melanoma and for the detection of postoperative metastases. Cysteinyldopa is believed to be formed by the rapid enzymatic hydrolysis of 5-S-glutathionedopa found in melanin-producing cells.	4.62	6	1	catecholamine; zwitterion

Condition	Indicated	Relationship Strength	Studies	Trials
Gallstone Disease [description not available]	0	1.96	1	0
Cholelithiasis Presence or formation of GALLSTONES in the BILIARY TRACT, usually in the gallbladder (CHOLECYSTOLITHIASIS) or the common bile duct (CHOLEDOCHOLITHIASIS).	0	1.96	1	0
Malignant Melanoma [description not available]	0	4.14	6	0
Cancer of Skin [description not available]	0	4.14	6	0
Melanoma A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445)	0	4.14	6	0
Skin Neoplasms Tumors or cancer of the SKIN.	0	4.14	6	0
Metastase [description not available]	0	1.98	1	0
Neoplasm Metastasis The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.	0	1.98	1	0
Nevi, Melanocytic [description not available]	0	1.99	1	0
Nevus, Pigmented A nevus containing melanin. The term is usually restricted to nevocytic nevi (round or oval collections of melanin-containing nevus cells occurring at the dermoepidermal junction of the skin or in the dermis proper) or moles, but may be applied to other pigmented nevi.	0	1.99	1	0
Albinism, Tyrosinase-Negative [description not available]	0	2.38	2	0
Albinism, Oculocutaneous Heterogeneous group of autosomal recessive disorders comprising at least four recognized types, all having in common varying degrees of hypopigmentation of the skin, hair, and eyes. The two most common are the tyrosinase-positive and tyrosinase-negative types.	0	2.38	2	0
B16 Melanoma [description not available]	0	1.97	1	0